Clinical trial

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

NCT05015010

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Alectinib Normalized identity: alectinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-05-20

PhasePHASE2

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

AlectinibDRUG · verified · RxNorm: alectinib

Sponsors & collaborators

Gruppo Oncologico Italiano di Ricerca Clinicalead sponsor

Mapped research locations

RomaItaly3 NaplesItaly1 GenovaItaly1 PadovaItaly1 BolognaItaly1 FlorenceItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05015010 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.